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Effect of zinc on the treatment of Plasmodium falciparum malaria in 
children: a randomized controlled trial1–3 
 
The Zinc Against Plasmodium Study Group 
 
ABSTRACT 
Background: Zinc supplementation in young children has been 
associated with reductions in the incidence and severity of diar- 
rheal diseases, acute respiratory infections, and malaria. 
Objective: The objective was to evaluate the potential role of zinc 
as an adjunct in the treatment of acute, uncomplicated falciparum 
malaria; a multicenter, double-blind, randomized placebo- 
controlled clinical trial was undertaken. 
Design: Children (n = 1087) aged 6 mo to 5 y were enrolled at 
sites in Ecuador, Ghana, Tanzania, Uganda, and Zambia. Children 
with fever and ≥ 2000 asexual forms of Plasmodium falciparum/J.L 
in a thick blood smear received chloroquine and were randomly 
assigned to receive zinc (20 mg/d for infants, 40 mg/d for older 
children) or placebo for 4 d. 
Results: There was no effect of zinc on the median time to reduc- 
tion of fever (zinc group: 24.2 h; placebo group: 24.0 h; P = 0.37), 
a ≥75% reduction in parasitemia from baseline in the first 72 h in 
73.4% of the zinc group and in 77.6% of the placebo group 
(P = 0.11), and no significant change in hemoglobin concentra- 
tion during the 3-d period of hospitalization and the 4 wk of fol- 
low-up. Mean plasma zinc concentrations were low in all children 
at baseline (zinc group: 8.54 ± 3.93 J.mol/L; placebo group: 
8.34 ± 3.25 J.mol/L), but children who received zinc supplemen- 
tation had higher plasma zinc concentrations at 72 h than did those 
who received placebo (10.95 ± 3.63 compared with 10.16 ± 
3.25 J.mol/L, P < 0.001). 
Conclusion: Zinc does not appear to provide a beneficial effect 
in the treatment of acute, uncomplicated falciparum malaria in 
preschool children.        Am J Clin Nutr 2002;76:805–12. 
 
KEY WORDS        Zinc, malaria, Plasmodium falciparum, 
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INTRODUCTION 
Childhood malaria is a major public health problem worldwide, 
with an estimated 2 million children dying of malaria yearly, pri- 
marily because of Plasmodium falciparum and its complications 
(1). Approximately 400 million people are estimated to suffer 
from malaria morbidity annually; two-thirds of those people reside 
in sub-Saharan Africa. 
Prompt diagnosis and early treatment continue to be the main- 
stays of the current approach to malaria control (2). Second-line 
drugs are often required to deal with chloroquine resistance, but 
their high cost and greater potential for adverse effects restrict 
their use in malaria-endemic countries. Because of the increasing 
prevalence of malaria, its associated morbidity and mortality in 
children, and the progressive increase in the resistance of the par- 
asite to antimalarial drugs (3), new treatment options are desper- 
ately needed. 
Children < 5 y old in malaria-endemic areas are at risk of protein- 
energy malnutrition, as well as deficiencies in micronutrients 
including zinc (4). Zinc deficiency in humans leads to growth 
retardation, thymic atrophy, lymphopenia, impaired T and B lym- 
phocyte function, impaired chemotactic activity of neutrophils, 
and a reduction in thymulin activity, interferon-')' concentrations, 
and the number of CD4 (helper) lymphocytes (5). These alter- 
ations in the cellular and humoral functions may increase host 
susceptibility to P. falciparum (5, 6). Zinc supplementation of 
children in developing countries has resulted in improvement of 
delayed cutaneous hypersensitivity (7) and an increase in CD4 
lymphocytes (8). Zinc supplementation has been shown to reduce 
the incidence of diarrhea and pneumonia (9) and to be beneficial 
when used as adjunctive therapy for acute diarrhea (10, 11). 
A community-based zinc supplementation trial in The Gambia 
designed to evaluate the effect of zinc on growth found a trend 
toward fewer health center visits for malaria by children who 
received zinc (12). In Papua New Guinea, zinc supplementation 
in preschool children reduced malaria-attributable health center 
visits by 38% (13). On the basis of the therapeutic benefits of zinc 
for acute and persistent diarrhea, zinc’s crucial role in immune 
system function, and recent evidence that zinc supplementation 
appears to reduce malaria morbidity, we examined the hypothesis 
that zinc given as an adjuvant to standard antimalarial therapy 
would improve the outcomes of acute episodes of P. falciparum 
malaria in children. 
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SUBJECTS AND METHODS 
Study design and sites 
The  study  was  a  multicenter,  double-blind,  randomized 
placebo-controlled clinical trial at the following sites: Hospital 
Delfina Torres (Esmeraldas, Ecuador), Komfo Anokye Teaching 
Hospital (Kumasi, Ghana), Kisarawe District Hospital (Kisarawe, 
Tanzania), Mpigi Health Center (Mpigi, Uganda), and Arthur 
Davison Children’s Hospital (Ndola, Zambia). These sites serve a 
mixture of urban and rural populations in Africa and Latin Amer- 
ica. The 4 African sites are in malaria-hyperholoendemic zones, 
whereas Ecuador is in a hypoendemic zone. Subject enrollment 
took place between December 1998 and May 2000. 
 
Study population 
All children aged 6–60 mo who presented to the participating 
health institution for evaluation of fever were screened for the 
study. A finger-stick blood sample was taken from children with 
an axillary temperature ≥ 37.5 oC. Children with ≥ 2000 asexual 
forms of P. falciparum/J.L in a thick blood smear were consid- 
ered eligible for enrollment into the trial. If the child did not meet 
any of the exclusion criteria and if his or her parent or caretaker 
was willing to give written, informed consent, then the child was 
enrolled in the study. Exclusion criteria included a hemoglobin 
concentration < 70 g/dL; severe malaria as defined by the pres- 
ence of any of the following: cerebral malaria, severe anemia, 
renal failure, pulmonary edema, hypoglycemia, shock, sponta- 
neous bleeding, or repeated convulsions (14); non-P. falciparum 
or mixed Plasmodium infections; concurrent severe infections 
(ie, lower respiratory infection, acute otitis media, pyelonephri- 
tis, typhoid fever, bloody diarrhea, meningitis, or measles); severe 
dehydration; malnutrition as defined by the Wellcome criteria 
(15) (ie, marasmus, kwashiorkor, or marasmic kwashiorkor); 
inability to tolerate oral medications or fluids; chronic illness 
(including tuberculosis, acquired immunodeficiency syndrome, 
severe congenital anomalies, sickle cell disease); and prior par- 
ticipation in this trial. 
 
Randomization and blinding 
Zinc and placebo tablets that were identical in appearance 
were packaged in identical polypropylene tubes labeled with 
subject identification numbers. Randomization was performed 
in blocks of 20 by using a table of random numbers and was 
stratified by site. Once a child was enrolled, the next container 
in the sequence was opened, and the corresponding regimen was 
provided to the child. Investigators, clinical staff, and patients 
were blinded to study group assignment. The study code was 
broken after completion of enrollment and follow-up of all 
study subjects. 
 
Treatment specification 
The zinc preparation that was used consisted of an effervescent, 
citrus-flavored tablet containing 25 mg Zn in the form of zinc sul- 
fate (Biolectra Zink; Hermes Arzneimittel GmbH, Munich, Ger- 
many) dissolved in 25 mL water. The placebo, a zinc-free tablet 
having color, taste, and appearance similar to those of zinc sulfate 
and that was especially prepared by Hermes Arzneimittel GmbH, 
was put into solution in an identical fashion. The strong lemon- 
lime flavor of the solution effectively concealed the metallic taste 
of zinc, thus preventing study participants or personnel from being 
able to determine whether a preparation contained zinc or placebo. 
Zinc was given in a total daily dose of 20 mg for children aged 
< 12 mo and 40 mg for children aged 12–60 mo. The zinc or 
placebo was administered in 2 equally divided daily doses during 
the first 3 d of the study and as a single dose on the fourth day. 
The drug was given under direct supervision 15–30 min before a 
meal. If the child vomited ≤ 15 min after drug administration, the 
dose was repeated. 
 
Clinical care of subjects 
 
Baseline evaluation 
Demographic data, information on the use of antivector meas- 
ures to prevent malaria or on recent antimalarial use, and signifi- 
cant medical history were obtained. A complete physical exami- 
nation, including vital signs, anthropometric measurements, 
hydration status, neurologic status according to the Blantyre coma 
scale (16), and abdominal examination to measure liver and spleen 
size, was performed. Subjects were admitted to the inpatient ward 
for 48–72 h. 
 
Inpatient care 
Clinical monitoring of patients included measurement of axil- 
lary temperature every 4 h and physician evaluation every 24 h or 
more frequently if clinically indicated. In addition, standard nurs- 
ing care was provided. All subjects received standard medical care 
for any concurrent illnesses that were present at baseline or that 
developed during the study. For these infections, the use of the 
antibiotics trimethoprim, sulfamethoxazole, erythromycin, and 
doxycycline was avoided because of their antimalarial effects. 
Paracetamol was administered for temperatures ≥ 38.5 oC at a dose 
of 10–15 mg/kg every 6 h. 
 
Antimalarial therapy 
Chloroquine was given as the first-line drug in accordance 
with the national treatment guidelines for malaria in all 5 coun- 
tries. The following schedule was used: 10 mg/kg on day 0, 10 
mg/kg on day 1, and 5 mg/kg on day 2. Tablets containing 
150 mg base were used. If either a treatment or parasitologic 
failure occurred, subjects were changed to a standard dose of 
either amodiaquine or sulfadoxine as second-line antimalarial 
therapy. Treatment failure was defined as the presence of axil- 
lary temperature ≥ 37.5 oC and parasitemia of > 25% of the base- 
line value at 72 h. Parasitologic failure was defined as para- 
sitemia of > 25% of the baseline value Swith resolution of fever 
(ie, temperature < 37.5 oC at 72 h). Children who developed cere- 
bral malaria or who failed to respond to second-line therapy were 
treated with quinine. If, during the course of treatment, the con- 
dition of the patient deteriorated or complicated malaria devel- 
oped, then the clinician had the option to change treatment as 
clinically indicated. Children with severe symptomatic anemia 
were given a transfusion of packed red blood cells. Discharge 
from hospital occurred once the fever had resolved (axillary tem- 
perature < 37.5oC for ≥ 12 h) and there was a ≥ 75% reduction in 
parasitemia relative to baseline. 
 
Outpatient follow-up 
Parents were asked to bring the subject back to the study site at 
72 h (if discharged at 48 h) and on the mornings of days 7, 14, and 
28. Parents were instructed to bring the child to the study site 
immediately if he or she developed fever or other signs of illness 
at any time between discharge and day 28. If the patient did not 
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return for follow-up, a research assistant went to the subject’s 
home to locate him or her. At each follow-up visit, subjects were 
asked about any illnesses since the last visit, especially those man- 
ifested by fever, and about any use of an antimalarial drug. Blood 
smears were obtained and hemoglobin concentrations were meas- 
ured at each follow-up visit. 
 
Criteria for withdrawal from the study 
If a subject, during the inpatient phase of the trial, developed 
coma or the inability to tolerate oral fluids or medicines, he or she 
was withdrawn from the assigned treatment arm of the study, but 
outcome data were still collected, including outpatient follow-up. 
If informed consent was withdrawn at any time during the trial, 
the subject was discharged from the study. 
 
Laboratory evaluation 
Giemsa-stained thick blood smears were made on admission 
(time 0); at 24, 36, 48, and 72 h; and on days 7, 14, and 28. The 
total parasite count per J.L was quantitated (17). A thick smear 
was declared negative after the viewing of high-power fields con- 
taining 500 white blood cells. Hemoglobin concentrations were 
determined by Hemacue (Angelholm, Sweden) on admission and 
on days 7, 14, and 28. Blood for plasma zinc was taken on day 0 
before the administration of the study drug and then at 72 h. Sam- 
ples were obtained just before meals. Venous blood was drawn 
with zinc-free syringes and placed into heparinized zinc-free 
tubes. Blood was immediately centrifuged and plasma was trans- 
ferred into zinc-free tubes with a plastic zinc-free pipet and frozen 
at -20 oC. Plasma zinc was assayed by atomic absorption spec- 
trophotometry at the University of Colorado Center for Human 
Nutrition. 
 
Outcomes 
Primary outcomes were the number of hours to the resolu- 
tion of fever (fever resolution time was defined as the time at 
which axillary temperature remained < 37.5 oC for 12 consec- 
utive hours) and the proportion of subjects with ≥ 75% reduc- 
tion in parasitemia at 72 h (compared with parasitemia values 
on admission). Secondary outcomes were the proportion of 
subjects who were aparasitemic at 72 h and on days 7, 14, and 
28; the mean change in hemoglobin from day 0 to days 7, 14, 
and 28; and the change in mean plasma zinc concentrations 
between time 0 and 72 h. 
 
Quality control 
 
Clinical measurements 
All investigators took part in a protocol development workshop 
during which the protocol was designed and a consensus was 
reached on the details of clinical care of children with acute 
malaria. Uniformity in the application of inclusion and exclusion 
criteria, as well as in case management, was emphasized, and a 
study manual was written. Training of study personnel and enroll- 
ment of 5 pilot subjects were performed at all sites. Technical staff 
made site visits at the beginning of enrollment to assess study pro- 
cedures. 
 
Laboratory measurements 
Hemoglobin measurements were made at all sites by using the 
same portable machine (Hemacue) and technique. Blood smears 
were performed in an identical manner at all sites. Internal quality 
control consisted of the duplicate reading of a 10% subsample of 
smears by an experienced parasitologist. External quality control 
on a 5% sample of slides from all sites was done by an experi- 
enced parasitologist who was not otherwise involved in the study 
(18). The comparison of the results of the external quality control 
of blood smears performed by an independent reader with the 
blood smear results found by the study parasitologist at each site 
yielded a mean (± SD) difference of 0.14 ± 3.55 between the 2 
groups in log-transformed parasite density counts. This means that 
there was an average difference in parasite density counts of 15% 
(with a large amount of variation) between the blood smear read- 
ings done at each site and those done by the external quality- 
control parasitologist. However, this difference was not signifi- 
cant (P = 0.59). 
 
Data management, statistical power, and statistical methods 
All case report forms were checked for missing, discrepant, 
and illogical responses by the study supervisor. The Applied 
Research for Child Health Project (Cambridge, MA) was the 
trial’s data coordinating center. Double data entry was per- 
formed; one entry was done at the site, and the second entry 
and validation were done at the Applied Research for Child 
Health Project. Data entry and management were carried out 
with EPI-INFO software, version 6.04c (Centers for Disease 
Control and Prevention, Atlanta) and Integrated Microcomputer 
Processing System, version 3.1 (US Bureau of the Census, 
Washington, DC). 
To obtain the proper sample size for the trial, we calculated 
the statistical power necessary to examine the effect of the 
supplements on each of the 2 primary outcomes, and the 
larger of the 2 sample sizes thus obtained was used. It was 
estimated that 25% of the children in the placebo group would 
fail to achieve ≥ 75% reduction in parasitemia at 72 h. Assum- 
ing a potential efficacy of 30% for the zinc regimen and a 
10% loss to follow-up, 1025 subjects were required for enroll- 
ment to answer the question with a power of 80% and a two- 
tailed level of significance of 5%. The assumption of a 30% 
beneficial effect of zinc supplements was based on a study 
from Papua New Guinea, in which zinc supplementation was 
associated with a 30% reduction in health center visits for 
malaria (19). 
All analyses were made according to the intention-to-treat prin- 
ciple. Frequencies of outcomes between treatment and control 
groups were compared by using the chi-square test (20). Differ- 
ences in medians between treatment and control groups were 
compared by using the Wilcoxon rank-sum test (20). The analy- 
sis of repeated-measures data used mixed-models regression (21). 
Differences in the hours to reduction in fever were compared by 
using the log-rank test for homogeneity for Kaplan-Meier sur- 
vival curves (22). In a subgroup analysis for the detection of effect 
modifiers, we used  binomial regression with the log link func- 
tion and simultaneously controlled for the study site (23). We used 
SAS software, version 7.0 (SAS Institute Inc, Cary, NC) for sta- 
tistical analysis. 
Ethical approval of the study was obtained from the institu- 
tional review boards at each site and at the Harvard School of Pub- 
lic Health. Written, informed consent was obtained from the par- 
ent or guardian of each subject. A data safety monitoring board 
consisting of 2 experts in infectious diseases and a biostatistician 
not otherwise involved in the trial performed a review of serious 
adverse events midway through the study. 
 
 
 
808 THE ZAP STUDY GROUP 
 
TABLE 1 
Baseline characteristics of subjects1 
 
 
 
Population characteristics 
 
 
 
Zinc group Placebo group 
(n = 542) (n = 545) 
Age (mo) 26.4 ± 15.92 27.0 ± 15.9 
Mother’s school attendance (y) 5.7 ± 3.6 5.7 ± 3.6 
Male (%) 52 52 
Breast-feeding (%) 41 39 
Use of bed nets (%) 22 24 
Antimalarial use in previous 7 d (%) 37 33 
Nutritional status 
Weight-for-age (z score) -1.08 ± 1.1 -1.16 ± 1.2 
Height-for-age (z score) -1.43 ± 1.5 -1.53 ± 1.5 
Weight-for-height (z score) -0.16 ± 1.2 -0.21 ± 1.3 
Midupper arm circumference (cm) 15.0 ± 1.4 14.9 ± 1.4 
Clinical data 
Axillary temperature (ºC) 38.7 ± 0.9 38.6 ± 0.9 
Splenomegaly (%) 4 3 
Laboratory data 
Parasitemia (/J.L)3 19 283 17 448 
(1 500–435 920)   (225–430 000) 
Hemoglobin (g/L) 92 ± 16 93 ± 16 
Plasma zinc 
(J.mol/L)   8.5 ± 3.9   8.3 ± 3.3 
(J.g/dL) 55.9 ± 25.7 54.5 ± 21.6 
1 There were no significant differences between the groups. 
2 –x ± SD. 
3 Geometric –x; range in parentheses. 
 
 
 
FIGURE 1. Study profile. 
 
 
 
RESULTS 
A total of 5930 persons were screened at the 5 study sites, and 
1087 subjects were enrolled (Figure 1). The distribution of 
enrollees was 77 children in Ecuador, 214 in Ghana, 260 in Tan- 
zania, 276 in Uganda, and 260 in Zambia. The most common rea- 
sons for ineligibility included the absence of fever at the time of 
health center presentation and the presence of severe anemia, mal- 
nutrition, or infection with Plasmodium vivax. The ratio of 
screened to enrolled patients was not equal at the sites. The 
African sites screened =2 patients for each patient enrolled, 
whereas the site in Ecuador screened an average of =35 patients 
for each patient enrolled. This imbalance in the rate of ineligibil- 
ity stemmed primarily from the need to exclude patients who did 
not have malaria as a cause of their fever; moreover, of those in 
Ecuador who did have malaria, about one-third had P. vivax, but 
this Plasmodium species was rarely encountered in the African 
sites. The baseline characteristics of the treatment (zinc) and con- 
trol (placebo) groups were not significantly different (Table 1). 
 
Zinc or placebo treatment 
Overall, 98.3% of the planned doses of zinc or placebo were 
given to the children. The percentage of children who did not 
take the planned dose did not differ significantly between the 
zinc and placebo groups. The amount of vomiting during the 
course of hospitalization did not differ significantly between the 
2 groups (12.7% in the zinc group and 12.1% in the placebo 
group, P = 0.76). 
Severe adverse events occurred in 35 subjects (Table 2). These 
included 2 episodes of cerebral malaria, 26 episodes of severe 
anemia requiring transfusion, 3 episodes of febrile convulsions, 
and 4 deaths. The incidence of severe adverse events did not dif- 
fer significantly between the 2 groups. The data safety monitoring 
board reviewed the severe adverse events and concluded that these 
were unlikely to be related to the study intervention. 
 
Primary and secondary outcomes 
Because there was no significant interaction between the effect 
of the supplements (zinc or placebo) and the sites (African sites 
or Ecuador) on the primary outcomes, all analyses include the 
data pooled from the 5 participating study sites. The Kaplan- 
Meier survival curves for time to resolution of fever are shown in 
Figure 2. The median time to reduction of fever did not differ 
significantly between the groups (24.2 compared with 24.0 h, 
P = 0.37). Of the 965 subjects whose fever resolved during the 
first 72 h, 638 received paracetamol, whereas 327 did not. There 
was no significant difference between the zinc and placebo groups 
 
 
TABLE 2 
Summary of severe adverse events1 
 
 Zinc group Placebo group 
Adverse event (n = 542) (n = 545) 
Cerebral malaria (n) 1 1 
Severe anemia (n) 17 9 
Febrile convulsion (n) 1 2 
Death (n) 2 2 
Total (n) 21 14 
1 There were no significant differences between the groups. 
Variables Zinc group Placebo group 
Aparasitemic subjects (%)   
72 h 20.2 [100 of 496] 21.5 [108 of 502] 
7 d 50.9 [258 of 507] 54.7 [280 of 512] 
14 d 54.6 [265 of 485] 53.6 [261 of 487] 
28 d 59.9 [277 of 462] 55.6 [263 of 473] 
 
 
 
 
TREATMENT OF FALCIPARUM MALARIA WITH ZINC 809 
 
TABLE 4 
Plasma zinc concentrations at baseline and 72 h1 
 
Plasma zinc concentration 
 
Study group Baseline 72 h 
Zinc group   
(J.mol/L) 
(J.g/dL) 
8.54 ± 3.93 
55.9 ± 25.7 
10.95 ± 3.632 
71.6 ± 23.72 
Placebo group   
(J.mol/L) 
(J.g/dL) 
8.34 ± 3.25 
54.5 ± 21.3 
10.16 ± 3.252 
66.5 ± 21.32 
FIGURE 2. Time to resolution of fever in the zinc (—) and placebo 
(—0—) groups. The median time to resolution of fever was not signifi- 
cantly different between the groups. 
 
 
in the number of children who received paracetamol. Of the chil- 
dren receiving paracetamol, 259 did not receive a dose before the 
resolution of fever, whereas 379 were given paracetamol at some 
point before the resolution of fever. Because fever resolution was 
defined as axillary temperature < 37.5 oC  for 12  consecutive 
hours, it was possible for study subjects to meet the definition of 
fever resolution and then have a recurrence of fever. Of the 259 
subjects who received their first dose of paracetamol after fever 
resolution, 258 had a temperature ≥ 37.5 oC after fever resolution. 
However, in 97% (368 of 379) of the children, the fever did not 
resolve for at least 13 h after they were last given paracetamol. 
Thus, paracetamol use was unlikely to have had any effect on the 
duration of fever. 
The proportion of children whose parasitemia value was 
reduced ≥ 75% in the first 72 h in the zinc group was 73.4% (398 
of 542) and that in the placebo group was 77.6% (423 of 545) 
(x2  = 2.57, P = 0.11). There also was no significant difference 
between the groups in the percentage of children who required 
second-line antimalarial therapy during the period of hospitaliza- 
tion (zinc group: 12.6%; placebo group: 12.3%). 
There were no significant differences in secondary outcomes 
between the 2 groups, except for the change in plasma zinc con- 
centration between 0 and 72 h. An analysis of data from the 
African sites alone (ie, excluding the data from Ecuador) revealed 
no significant difference between the zinc and placebo groups in 
any of the secondary outcomes. With antimalarial treatment, about 
one-fifth of the children in both groups were aparasitemic at 72 h 
 
 
 
TABLE 3 
Percentage of aparasitemic children and mean change in hemoglobin 
concentration in the zinc and placebo groups1 
 
 
 
 
 
 
 
Change in hemoglobin 
from day 0 (g/L) 
7 d -4.9 ± 17.2 [502] -4.8 ± 18.4 [519] 
14 d 3.4 ± 17.9 [476] 2.6 ± 17.4 [477] 
28 d 9.3 ± 18.8 [454] 7.5 ± 18.9 [463] 
1 –x ± SD; n in brackets. There were no significant differences between 
the groups. 
1 –x ± SD. The data were analyzed with repeated measures with the use 
of mixed models with an interaction for treatment and time. There was a 
significant interaction between group and time, P = 0.038. 
2 Significantly different from baseline, P < 0.001. 
 
 
 
(Table 3). The proportion of children in both groups who were 
aparasitemic had increased to nearly 60% by day 28. More than 
19% (207 of 1087) of the children received second-line anti- 
malarials between days 7 and 28. 
At 72 h, plasma zinc concentrations had increased in both 
groups (Table 4). Although there was no significant difference in 
baseline plasma zinc concentrations between the groups (Table 1), 
the children who received zinc supplements had significantly 
larger increases in zinc concentrations between baseline and 72 h 
than did the children who received placebo [0.59 ± 0.28 J.mol/L 
(3.8 ± 1.8 J.g/dL), P = 0.038]. 
The primary outcome of the reduction of parasitemia by 75% at 
72 h was modeled by using binomial regression (22). No signifi- 
cant differences in outcomes between the groups were found after 
controlling for age group, weight-for-age z score, maternal edu- 
cation, breast-feeding, use of bed nets, prior chloroquine use, sec- 
ond-line antimalarial use, baseline plasma zinc concentration, and 
study location. The presence of effect modifiers was tested by 
using binomial regression in which study location was controlled 
for. No difference in treatment effect was found with any of the 
categories of effect modifiers that were tested (sex, baseline 
plasma zinc, baseline hemoglobin, weight-for-age z score, 
height-for-age z score, weight-for-height z score, and baseline par- 
asitemia). 
 
 
DISCUSSION 
We found that zinc as an adjuvant to the treatment of uncom- 
plicated P. falciparum malaria in children aged 6–60 mo had no 
effect on the duration of fever or on the reduction of parasitemia 
at 72 h. In addition, there was no apparent effect of the interven- 
tion on hematologic or parasitologic measures during the 4 wk of 
follow-up. 
The 2 previous studies that showed a beneficial effect of zinc in 
malaria were community-based prevention trials (12, 13). The 
first, a placebo-controlled study in which preschool children in 
rural Gambia received zinc supplements twice weekly for 1.25 y 
(12), showed a trend toward a reduction in the number of clinic 
visits for malaria (P = 0.09). The small sample size of that study 
most likely did not provide adequate power to allow the detection 
of an effect of zinc supplementation on the rates of clinic visits 
for malaria. In addition, the twice-weekly dosing interval may 
have been responsible for the failure of the zinc supplement to 
significantly increase zinc concentrations in plasma or hair 
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relative to those found in the placebo group. In a more recent, 
larger supplementation trial in preschool children in Papua New 
Guinea (13) in which zinc was administered daily for 46 wk, there 
was a significant reduction in episodes of P. falciparum malaria. 
The greatest effect of the zinc intervention was observed in chil- 
dren   with   P.   falciparum   episodes   accompanied   by   para- 
sitemia ≥ 100 000 parasites/J.L. However, in contrast to these 2 
studies, a recent study in Burkina Faso found that 6 mo of zinc 
supplementation had no effect on the incidence of symptomatic 
falciparum malaria, severity of malaria episodes, or other malari- 
ometric indexes (24). 
The lack of efficacy of zinc in our trial may be due to a num- 
ber of factors. First, the duration of the supplementation in this 
study was purposefully short. The intervention was designed to be 
administered in conjunction with antimalarial therapy in a way 
that would be practical in the developing world. Previous studies 
examining the therapeutic role of zinc in acute infections have also 
taken this approach (10, 11, 25). The beneficial role of zinc in the 
treatment of diarrhea may be due to a direct effect of zinc on intes- 
tinal function by virtue of improved absorption of water and elec- 
trolytes (26, 27), early regeneration of the epithelial lining (28, 29), 
and improved production of brush border digestive enzymes (30, 31). 
In contrast, for zinc to have a beneficial effect on malaria, there 
may need to be improvements in the functioning of the immune 
system. It is not known how long it takes zinc supplementation to 
lead to a resolution of abnormalities of immune function when it 
is used to treat zinc deficiency. Three days of zinc supplementa- 
tion may have been insufficient to allow for the improvement of 
immune function in children with underlying zinc deficiency, 
whereas longer periods of supplementation clearly do lead to bet- 
ter immune function (5, 7, 8). The duration of zinc supplementa- 
tion may explain the difference between our results and those of 
the studies of zinc that found this micronutrient to be beneficial in 
the prevention of malaria (12, 13). 
Second, treatment with zinc would be unlikely to be beneficial 
if the study subjects had normal zinc nutritional status. The study 
participants, however, resided in areas where there is a high risk 
of zinc deficiency because of cereal-based diets, which are rela- 
tively low in zinc and high in phytates (32, 33). Accurate assess- 
ment of zinc status is difficult and optimally should involve the 
use of multiple measures (34). However, many of the more sophis- 
ticated measures of zinc status such as platelet, lymphocyte, or tis- 
sue zinc concentrations are not practical for large field studies in 
developing countries. In addition, these measures have not been 
validated as markers of zinc status. Although plasma zinc con- 
centrations are commonly used as a surrogate marker of zinc sta- 
tus in many clinical trials, plasma zinc represents < 0.2% of total 
body zinc stores, and there is a poor correlation between plasma 
zinc concentrations and body stores (35). In addition, it is recog- 
nized that acute infections and febrile illnesses decrease plasma 
zinc concentrations, although the extent and timing of this 
decrease are unclear (36). The magnitude of the decrease in 
plasma zinc concentrations in persons with acute infections has 
been shown in animal models to be a function of the stage, dura- 
tion, and severity of the infection (37–39). Although some com- 
munity-based studies found minimal to no suppression of plasma 
zinc concentrations in infected children compared with that in 
uninfected children (40–42), it is possible that the severity of ill- 
ness in these studies was not great enough to cause a significant 
decrease in plasma zinc. The baseline plasma zinc concentrations 
in our study cohort were initially very low, but they increased as 
the acute episode of malaria resolved. This suggests that the 
plasma zinc concentration had been depressed as part of the acute 
phase response. However, even after resolution of fever, the 
plasma zinc concentrations remained relatively low, with a mean 
concentration of < 10 J.mol/L at 72 h in the placebo group. This 
suggests that, in our study population, there may have been a com- 
bination of low plasma zinc concentration in response to the acute 
infection and an underlying zinc deficiency. Because the children 
who were treated with zinc had significantly higher plasma con- 
centrations at 72 h, it appears that there was good bioavailability 
of the supplement. However, the absolute magnitude of the dif- 
ferences in plasma zinc between the zinc and placebo groups was 
relatively small (0.7 J.mol/L, or 5.1 J.g/dL). The physiologic or 
clinical significance of this relatively small difference is unclear. 
Third, the dose of zinc used may not have been adequate. 
Higher zinc doses may conceivably have had a stronger effect, but 
we felt that a dose that was 4 times the US recommended dietary 
allowance (43) was a reasonable one. The mean daily dose, based 
on the mean baseline weights of the children who received zinc, 
was 2.5 mg/kg for children aged 6–11 mo and 3.4 mg/kg for those 
aged 12–60 mo. This amount of zinc was well tolerated, resulted 
in a significantly higher final plasma zinc concentration than did 
placebo, and was not associated with any serious adverse events 
in our study. High-dose zinc (6.0 mg · kg-1 · d-1) has been associ- 
ated with increased mortality in severely malnourished children 
(44). In addition, high doses of zinc have been associated with the 
impairment of immune responses in healthy adults (45). 
Fourth, the use of paracetamol may have masked a potential 
effect of zinc on parasitemia. A randomized trial in Gabon of chil- 
dren who were being treated for P. falciparum malaria found that 
a significantly greater amount of time was needed for parasite 
clearance in children treated with paracetamol than in those 
treated with mechanical antipyresis alone (46). Although the 
results of that study suggest that the approach used to manage 
fever in children with malaria may have an influence on the dura- 
tion of parasitemia, it is unlikely that the use of paracetamol in 
our study interfered with a potential effect of zinc, because the 
proportion of children treated with paracetamol in the placebo and 
zinc groups was similar, and fever was not resolved in most of the 
children for > 12 h after receipt of paracetamol. 
Unlike the situation at the site in Ecuador, where many children 
were excluded from participation because of the absence of 
malaria or the presence of P. vivax, the ineligibility rate for the 
African sites was < 50%. The aim of this study was to evaluate the 
intervention in a population that would be representative of those 
children presenting to urban or rural health care centers with 
acute, uncomplicated falciparum malaria. The final cohort of chil- 
dren fit this description. Because of the decision to focus only on 
malaria due to P. falciparum (which is the major source of mor- 
bidity and mortality worldwide), the results of this study cannot be 
generalized to areas where other species of Plasmodium are com- 
monly encountered. However, the findings of this study can be 
applied to many developing countries where P. falciparum is 
endemic, because the study’s multicenter design with site-by-site 
differences in the extent of underlying immunity to malaria and 
in the intensity of malaria transmission allows a high degree of 
generalizability. Moreover, the large sample size reduced the 
chance of a type 2 error. Multiple measures of quality control, ade- 
quate blinding and randomization, and excellent intrasite agree- 
ment in reading blood smears all ensured the internal validity of 
the trial. 
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In conclusion, in this large randomized trial, we found no evi- 
dence that supplemental zinc, given as an adjuvant to standard 
chemotherapy, was helpful in the treatment of acute malaria in 
young children. However, because there may be benefits of zinc 
supplementation in the prevention of malaria morbidity (12, 13), 
additional community-based studies are needed to clarify the pro- 
phylactic role of this essential micronutrient in countries with 
endemic malaria.                                                                           
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